TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program

New England Journal of Medicine

Volumn 355, Issue 3, 2006, Pages 241-250

  Florez, Jose C ^a   Jablonski, Kathleen A ^a   Bayley, Nick ^a   Pollin, Toni I ^a   De Bakker, Paul I W ^a   Shuldiner, Alan R ^a   Knowler, William C ^a   Nathan, David M ^a   Altshuler, David ^a  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; METFORMIN; PLACEBO; TROGLITAZONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DNA POLYMORPHISM; FEMALE; GENE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HEALTH PROGRAM; HOMOZYGOTE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INSULIN RELEASE; INSULIN SENSITIVITY; LIFESTYLE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION FACTOR 7 LIKE 2 GENE;

COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; ENTEROENDOCRINE CELLS; FEMALE; GENE FREQUENCY; GENOTYPE; GLUCOSE METABOLISM DISORDERS; HUMANS; INCIDENCE; INSULIN; INSULIN RESISTANCE; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS; TCF TRANSCRIPTION FACTORS;

EID: 33746075560     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa062418     Document Type: Article

References (26)

1. Barroso I. Genetics of type 2 diabetes. Diabet Med 2005;22:517-35.
2. Florez JC, Hirschhorn JN, Altshuler D. The inherited basis of diabetes mellitus: implications for the genetic analysis of complex traits. Annu Rev Genomics Hum Genet 2003;4:257-91.
3. Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med 2001;345:971-80.
4. Grant SFA, Thorleifsson G, Reynisdottir I, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006;38:320-3.
5. Freely associating. Nat Genet 1999;22:1-2.
6. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. Nat Genet 2001;29:306-9.
7. Lohmueller K, Pearce CL, Pike M, Lander ES, Hirschhorn JN. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 2003;33:177-82.
8. Hattersley AT, McCarthy MI. What makes a good genetic association study? Lancet 2005;366:1315-23.
9. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
10. Idem. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 1999;22:623-34. [Erratum, Diabetes Care 1999;22:1389.]
11. Gabriel SB, Schaffner SF, Nguyen H, et al. The structure of haplotype blocks in the human genome. Science 2002;296:2225-9.
12. Tang K, Fu DJ, Julien D, Braun A, Cantor CR, Koster H. Chip-based genotyping by mass spectrometry. Proc Natl Acad Sci U S A 1999;96:10016-20.
13. Sluiter WJ, Erkelens DW, Reitsma WD, Doorenbos H. Glucose tolerance and insulin release, a mathematical approach. I. Assay of the β-cell response after oral glucose loading. Diabetes 1976;25:241-4.
14. Phillips DI, Clark PM, Hales CN, Osmond C. Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabet Med 1994;11:286-92.
15. Hanson RL, Pratley RE, Bogardus C, et al. Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies. Am J Epidemiol 2000;151:190-8.
16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
17. The Diabetes Prevention Program Research Group. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the Diabetes Prevention Program: effects of lifestyle intervention and metformin. Diabetes 2005;54:2404-14.
18. Greenberg RS, Kleinbaum DG. Mathematical modeling strategies for the analysis of epidemiologic research. Annu Rev Public Health 1985;6:223-45.
19. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979;6:65-70.
20. The Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005;54:1150-6.
21. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K. A comprehensive review of genetic association studies. Genet Med 2002;4:45-61.
22. O'Rahilly S, Barroso I, Wareham NJ. Genetic factors in type 2 diabetes: the end of the beginning? Science 2005;307:370-3.
23. Lyssenko V, Almgren P, Anevski D, et al. Genetic prediction of future type 2 diabetes. PLoS Med 2005;2(12):e345.
24. Yi F, Brubaker PL, Jin T. TCF-4 mediates cell type-specific regulation of proglucagon gene expression by β-catenin and glycogen synthase kinase-3β. J Biol Chem 2005;280:1457-64.
25. Nielsen E-MD, Hansen L, Carstensen B, et al. The E23K variant of Kir6.2 associates with impaired post-OGTT serum insulin response and increased risk of type 2 diabetes. Diabetes 2003;52:573-7.
26. Florez JC, Burtt N, de Bakker PIW, et al. Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region. Diabetes 2004;53:1360-8.